This compound and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate (ADC)
Polatuzumab vedotin, an investigational anti-CD79b ADC, is currently in clinical development based on its potential to selectively bind to B cells. CD79b is a transmembrane protein expressed on the surface of B cells as part of the B cell receptor complex. In preclinical in vitro models, data have shown polatuzumab vedotin to effectively and selectively eliminate cells expressing CD79b.1 Polatuzumab vedotin continues to be investigated in ongoing clinical studies.
1 Polatuzumab vedotin is an investigational anti-CD79b ADC currently being studied for its potential to selectively bind to CD79b expressed on B cells.1,2
2 Polatuzumab vedotin is designed to bind to the CD79b portion of the B cell receptor and become internalized by the cell where the cytotoxic agent, monomethyl auristatin E (MMAE), is then released.2,3
3 Preclinical data have shown that polatuzumab vedotin induced tumor regression in multiple xenograft models.1 Polatuzumab vedotin continues to be investigated in ongoing clinical studies.
- Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616-623. PMID: 17374736
- Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721-2729. PMID: 19633198
- Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs. 2012;4:637-647. PMID: 22909934